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To investigate efficacy of synthetic SPc5-12 promoter expression in 
skeletal and heart muscles and compare its activity with that of MYODI and 
MYLK2 muscle specific promoters. We hypothesized that we could achieve 
efficient, safe and global cardiac and muscle gene transfer in mice following 
a single intravenous injection of scAAV-SPc5-12-luc2 vector.  
We reported relatively robust levels of luciferase expression in the heart and 
moderate levels in the skeletal muscles in particular the tibialis and 
gastrocnemius which are representative of fast twitch muscle fibers. No 
significant luciferase expression was observed in other tissues such as liver, 
lung, spleen and brain. The result of the luciferase expression quantified as 
(photons/sec/cm2/steridian) in the individual dissected organs were similar to 
the optical imaging results observed of the whole mice. This study report for 
the first time that the SPc5-12 promoter delivered by AAV9 serotype is 
robust and muscle specific.  
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Introduction 
Duchenne muscular dystrophy (DMD) is X-chromosome-linked 
recessive neuromuscular disorder found in 1 in 3500 live male births (Singh 
et al. 2010; Willmann., 2009). The disease is associated with continuous 
cycles of muscle cell regeneration and degeneration, ultimately resulting in a 
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failure of muscle regeneration. Symptoms include constant falling and out 
turned knees appear as early as age two and during extreme DMD, patients 
are unable to sit upright, move their arms or legs, or breathe on their own 
(Singh et al., 2010). Patient’s life span rarely exceeds early mid-twenties due 
to cardiac or respiratory failure. This fatal muscle wasting diseases is caused 
by small deletions or point mutations that introduce a stop codon resulting in 
very little or no dystrophin production (Yue et al., 2008; Anderson et al., 
2006; Dunant., 2003). The dystrophin gene spans 2.9 Mb, consisting of 79 
exons and is expressed as a 14-kb transcript in muscle cells (Anderson et al., 
2006). In normal skeletal muscle, dystrophin is localized to the cytoplasmic 
surface of the sarcolemma, where it is involved in a series of molecular 
interactions forming a mechanical or structural link between the actin based 
myofiber cytoskeleton and sarcolemma transmembrane glycoprotein 
complex (de León et al., 2005; singh et al., 2010) hence it stabilizes muscle 
cell membrane during cycles of contraction and relaxation (Willmann., 
2009). The protein also plays a role in regulating the activity of membrane 
proteins as well as acting as a structural component of the membrane (Jeffrey 
S Chamberlain., 1993). The absence of dystrophin in DMD leads to a loss of 
function of the sarcolemma, causing the muscle fibers to be brittle and 
susceptible to membrane stress, this in turn leads to sarcolemmal fragility, 
muscle weakness and even muscle cell necrosis. In addition to its protective 
role, dystrophin has been proposed to act as a signaling molecule in the cell 
signaling pathways such as muscle cell growth, cytoskeleton organization, 
muscle homeostasis and atrophy/hypertrophy (Rando ., 2001)  
Promising findings to treat DMD are emerging from gene therapy 
strategies in which the ultimate aim is to correct dystrophin disorder by 
stable transfer of a functioning gene into cells to ensure the permanence of 
the correction (Eldestein ., 2007; Rodino-Klapac et al., 2007) . To achieve 
this goal, appropriate regulatory elements that impart tissue-specific 
transgene expression in cardiac and skeletal muscle need to be identified 
(Anderson et al., 2006). 
 
Materials and methods 
Generation of constructs  
scAAV expression plasmid designated pdsAAVscMONKEY 
(6199bp) was digested using appropriate enzymes ACC651 (GGTACC) and 
SphI (GCATGC) to remove unwanted Serp enhancer, TTRm promoter, 
MTTR 5’utr, MVM intron, FIX Co MT and bGH polyA fragments in order 
to replace a novel muscle specific expression cassette into this scAAV vector 
back bone (4001bp). Primers were designed to PCR out SPc5-12 promoter 
region from Human MDI plasmid. PCR was carried out using Finnzymes 
Phusion Hot start II High fidelity DNA polymerase Kit, the DNA 
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polymerase possess DNA polymerase and exonuclease activity. MVM intron 
to promote mRNA stability, sv40PA and luciferase Reporter gene sequences 
were synthesized and cloned into scAAV plasmid under the control of the 
synthetic muscle restrictive promoter Spc5-12.  
 
Tissue culture   
HEK 293 cells were seeded at 70% confluent and co-transfected with 
the expression plasmid (pdAAVsc-SPc5-12-MVM-Luc2-sv40pA), rAAV2/9 
plasmid and Adenoviral helper plasmid (Stratagene) using calcium 
phosphate transfection kit supplied by Invitrogen. Cell pellets were harvested 
48 hours post transfection, lysed by three freeze and thaw followed by 
sonication to release the viral particles. Cell suspension was purified by 
centrifugation at 3600rpm, 40c, 25 mins. The lysate were layered on a 
celsium chloride gradients and overnight centrifugation performed  at 
25,000rpm, 150c, 90Ti rotor, 18-20hrs and subsequently at 59,500rpm, 150c, 
80Ti rotors, for 20-24hrs. The gradient fractions between 1.3670-1.3740 RI 
containing rAAV particles was determined using Abbe refractometer, 
isolated and dialyzed/concentrated against sterile 10ml PBS 1 mM Mgcl2, 
through an Amicon ultracentrifugal filter Millipore. 
 
Vector titration 
The number of vector genome was determined relative to a plasmid 
DNA standard using quantitative PCR in ABI7500 FAST (Sequencer 
Detector Unit from Applied Biosystems, Foster, CA, USA) using SYBR 
Green mix and luciferase specific primers Forward-
CCCACCGTCGTATTCGTGAG and Reverse-
TCAGGGCGATGGTTTTGTCCC used to detect luciferase as transgene 
DNA target sequence.The sample (vector) was further diluted in the ratio of 
1: 250 and a reaction mix containing ABI SYBR Green Mix, primers, and 
water to top up to required volume was put in each reaction well. After 
loading the samples, standard and the negative control (water) onto the 96 
well Q-PCR plate, the Q-PCR was run from ABI7500 standard running: 
50°C for 10minute, 95°C for 2 minutes and subsequent 40 cycles of 95°C for 
15seconds and 60°C for 1 minute making each run last for about 1 hour and 
35 minutes. Samples were loaded in triplicates. 
 
Animal studies 
Animal studies were approved by the institutional Animal Ethical 
Commission. 5x109 vector genomes (vg) were injected (i.v) into the tail vein 
of Neonatal CB17-SCID mice purchased from Taconic Breeding 
Laboratories. Negative control mice were injected with 1X DPBS. The 
animals were held in the tail vein position and their tails were warmed before 
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the injection. The injections into the veins were carried out using 28 gauge 
needles. All the mice recovered from the injection quickly without loss of 
mobility or interruption of grooming activity. 
 
In vivo imaging  
All images were acquired using a biospace in vivo photo Imaging 
System (IVIS). The CCD was cooled to -230C and the field of view (FOV) 
set at 25-cm height of the sample shelf. The charged coupled device (CCD) 
camera operates by converting photons that strike the CCD pixel into 
electrons at wavelengths between 400-100nm, allowing visible detection 
through infrared light signals. The mice were anesthetized with 2% 
isofluorane and oxygen. D-luciferin substrate was then injected 
intravenously, at a dose of 15 μg/g of body weight. The mice were then 
placed in a light-tight chamber and images generated using a cryogenically 
cooled charge-coupling device camera. For each mouse, the images were 
taken at a photo acquisition time limit of 10 minutes after the substrate 
injection and emitted light images of mice collected. The visual output 
represented the number of photons emitted/second/cm2/steridian (sr) as a 
color image where the maximum was red and the minimum dark blue. 
Following imaging, the animals were kept warm with lamps and allowed to 
recover in the cages. All mice were imaged on a weekly schedule after AAV 
vector injection. 
 
Quantifying luciferase expression in mice  
For quantification of transmitted light signals, at 7 weeks post 
injection, the mice were killed and selected organs were dissected: brain, 
heart, liver, lung and skeletal muscles (biceps, triceps, quadriceps, tibialis 
and gastrocnemius). Region of interest (ROI) were drawn around each organ 
area and the bioluminescence signals emitted obtained as photons/sec/cm2/sr.   
 
Reverse transcriptase-polymerase chain reaction (RT-PCR)  
Quantitative RT-PCR was used to detect mRNA abundance for 
luciferase in all the twelve different tissues isolated. Messenger RNA 
(mRNA) was first extracted using an RNeasy kit (Qiagen) and then total 
mRNA concentration determined by Spectrophotometry using a Nanodrop. 
Superscript TM III First strand Synthesis system kit (Invitrogen) was used to 
convert mRNA from each sample into first strand cDNA. RNA primer mix 
in a final volume of 10ul/rxn (100ng total RNA, 50µM oligodT, 10mM 
dNTP mix, DEPC-treated water) was incubated at 650c for 5mins and placed 
in ice for 1 min. Added to CDNA synthesis mix in a final volume of 10ul per 
reaction (1 of 10x reverse transcriptase buffer, 4ul of 25Mm Mgcl2, 2ul of 
0.1M DTT, 1ul of 40U/ul RNaseOUT, 1ul of 200U/ul superscript TM III RT. 
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The reaction was incubated at 500c for 50 mins and the reaction terminated at 
850c for 5 minutes then chilled on ice. 
Real time PCR was performed with a reaction mixture for each 
sample of 2.5 ul forward primer (20 nmol/l), 2.5 ul reverse primer (20 
nmol/l), 2.5 ul RNAse-free DNAse-free water, and 12.5 ul SYBR Green 
Master Mix (ABI). Specific luciferase primers 
CCCACCGTCGTATTCGTGAG (forward) and 
TCAGGGCGATGGTTTTGTCC (reverse) was used in the reaction.  
For each experiment, a reaction mix was prepared; for each tube 
Aliquots (20 ul) of this mix were placed in the tubes and 5 ul cDNA solution 
was added to each reaction. All reactions were processed in triplicate. The 
experimental run protocol was denaturation (95 °C for 10 minutes) and 40 
cycles of 95 °C for 15 seconds, 60 °C for 30 seconds, 72 °C for 30 seconds 
with a single fluorescence measurement. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) cDNA served as the internal control gene for 
normalization of sample loading. 
 
Results 
Kinetics of scAAV9-SPc5-12-luc2 vector mediated gene expression in 
mice  
In this study we examined transduction efficiency and biodistribution 
of SPc5-12 muscle specific synthetic promoters in AAV9 following tail vein 
injection of newborn mice with 5x109 vector genome per mouse. To 
visualize localization pattern of luciferase and vector biodistribution profile, 
mice were assessed by quantifying luciferase expression at a weekly time 
point interval using an in vivo bioluminescent photo imaging system. The 
heart exhibited the strongest level of luciferase signals (greenish red color) 
followed by skeletal muscles that had moderate luciferase signals (light blue 
color). No significant signals were detected in other organs like liver, lung, 
brain, diaphragm and spleen. This result also demonstrated that scAAV9–
SPc5-12-luc2 vector efficiently transduced both the heart and skeletal 
muscles irrespective of the animal gender (Fig.1). 
  




Figure 1: Optical imaging of luc2 reporter gene expression in vivo. Imaging was performed 
for firefly luciferase (luc2) expression after intravenous injection of D-luciferin substrate 
(15ug/g). Study mice transfected with AAV9-SPc5-12-luc2 (5X109) emitted significant 
cardiac luc2 activity (greenish red color) at 4, 5, 6 and 7 week post injection. Moderate luc2 
activity (dark blue color) was observed in skeletal muscle. The control mice administered 
with PBS showed only background signals. 
 
In vitro luciferase Assay in selected tissues  
To observe differential expression driven by SPc5-12 promoter in 
specific tissues, seven weeks post injection the mice were euthanized and 
heart, spleen, liver, lung, kidney, diaphragm, brain and different skeletal 
muscle tissues from the leg and thigh (tibialis, gastrocnemius, quadriceps, 
triceps and biceps) were dissected out and observed under the imaging 
machine (Fig. 2). The results obtained correlated with the data observed 
during serial optical in vivo bioluminescence imaging. Gene transfer was 
more efficient in the heart than any other organ with an extensive region of 
the myocardium organ displaying intense luciferase signals (reddish-green 
light). Most of the skeletal, leg muscles (gastrocnemius and tibialis) and 
thigh muscles (quadriceps and biceps) yielded intermediate levels of 
luciferase signals. Moreover, there was no significant luciferase expression 
in other tissues such as lung, spleen, liver, kidney, brain and diaphragm. 






Figure 2: Representative bioluminescence images of luc2 expression in the different tissues 
of the neonatal mice. Luc2 expression could be observed in heart and skeletal muscles such 
as tibialis, quadriceps, biceps and gastrocnemius. The negative control mice injected only 
with PBS without the vector construct did not exhibit any luciferase expression. 
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To further verify whether the bioluminescence data obtained during 
non invasive optical imaging reflects actual luciferase activity observed in 
vitro, we plotted graphs of luciferase signals (photons/sec/cm2/sr) emitted 
against the different tissues of mice to effectively analyze the organs which 
were robustly transduced by scAAV9-SPc5-12 construct (Fig3). The 
luciferase expression signals obtained from the individual organs confirmed 
the biodistribution patterns observed during optical imaging. The main 
expression was in the heart which displayed the highest luciferase signals 
(1.30E+06) followed by quadriceps, gastrocnemius and tibialis of the 




Figure 3: Plot of luciferase activity in different tissues of mice. Signal intensities 
represented as photons/sec/cm2/sr plotted against the different tissues. The heart muscle 
still emerged as the best transduced organ, followed by the skeletal muscles such as 
quadriceps, gastrocnemius and tibialis. Signal intensities in the lung, liver, kidney, brain 
and spleen are insignificant. No luc2 signals were obtained in the negative control mice. 
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RT-PCR and genomic copy number assays are currently ongoing to 
further confirm if the levels of luciferase mRNA and remaining viral genome 
copy numbers in the heart, skeletal tissues and all the other different organs 
mimics the results observed during luciferase localization pattern and the 
analyzed levels of luciferase signals (photons/cm2/radian) using the BLI 
machine .  
This imaging data shows that the SPc5-12 promoter is robust and 
specific for cardiac and moderate for skeletal tropism. The non targeted 
tissues such as liver normally efficiently transduced by AAV9 serotype did 
not express luciferase despite the presence of substantial amount of vector 
genomes injected. A reasonable explanation for this is that the SPc5-12 
promoter incorporated in our expression cassette was not active in these 
other tissues rather was specific for heart and skeletal muscle. It has been 
shown that gene expression in the skeletal muscles following systemic 
delivery can be increased by using muscle specific promoters such as SPc5-
12 element that has been reported to restrict transgene expression to the 
skeletal muscle cells (Li et al 1999). 
  
Discussion  
Gene therapy aims to target the various underlying cellular and 
molecular abnormalities causing a disease and it has a great potential for the 
treatment of several diseases which no definite pharmacological agents exists 
i.e. heart failure, muscular dystrophies and cystic fibrosis (Zincarelli et al., 
2008). Many genetic diseases affect multiple organs/tissues and the 
challenge for gene therapy for these diseases lies in delivery of the 
therapeutic gene to all the affiliated tissues. More than 50% of the gene 
therapy clinical trials are currently using viral vectors for efficient gene 
delivery (Daya & Berns., 2008) and recombinant adeno-associated virus 
vectors (rAAVs) has emerged as one of the most promising vectors for 
systemic and local long term delivery of gene therapy for clinical diseases 
(Akache et al., 2006; Aikawa et al., 2002). There persistence in a wide range 
of tissues, lack of pathogenicity, physical stability and divergence of the 
capsid sequence in the new serotypes has resulted in striking differences in 
their transduction profile (Ghosh et al., 2007; Akache., 2006, Aikawa.,2002). 
The promiscuous tropism of AAV may lead to undesirable expression of 
therapeutic genes in non-targeted cells and this limitation can be 
circumvented by use of tissue specific promoter i.e. SPc5-12 (X. Li et 
al.,1999) to specifically drive the gene of interest to target tissues as cardiac 
and skeletal using rAAV. Body wide dissemination has particularly been 
reported for AAV 6, 8 and 9 hence this vectors are of major interest to cure 
many genetic diseases that requires global transduction of all the affected 
tissues i.e. in the case of gene therapy of DMD where mortality results from 
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severe pathology not only in the skeletal muscles but also heart, successful 
gene therapy may require lifelong expression of therapeutic gene in all the 
affected muscles and this vectors have been found to have the ability to 
transduce both cardiac and skeletal muscles (Foster et al. 2008; Rodino-
Klapac et al. 2007).  
When developing gene therapy constructs, it is important to minimize 
adverse responses to protein expression in unnecessary sites by restricting 
transgene expression to areas where most suitable. An approach to confine 
and or to increase specificity is to use a gene delivery vehicle with high 
tropism for the tissue of interest and select a promoter that drives the 
expression of a particular gene in the tissue(s) of interest (Pacak et al., 2008). 
The synthetic SPc5-12 promoter used in our study has been reported to have 
in vivo specificity in cardiac and skeletal muscle tissues and that their 
transcriptional potency greatly exceeds transcriptional levels obtained from 
natural myogenic and viral gene promoters ( Li et al., 1999). Studies have 
also shown that robust expression system requires interplay between 
Transcription factor complexes binding to the multiple TFBS of a promoter 
and enhancer regulatory regions (Li et al., 1999). This study explored the 
potential of systemic gene transfer with scAAV9 and SPc5-12 muscle 
specific promoter to direct expression of luciferase gene to targeted skeletal 
and heart tissues. Comparative studies are still currently underway with 
MYOD1 and MYLK2 promoters to determine the most robust and specific 
promoter conferring long-term and tissue-specific transcriptional activity in 
the muscles. In this study, rAAV- Spc5-12-luc2-MVM-sv40 construct was 
successfully cloned and all the clones were confirmed using multiple 
restriction enzymes analysis. The corresponding AAV9 vector was produced 
and 95% transfection efficiency was achieved 48 hr after transfection. This 
step was crucial to achieve good AAV vector titer after production. We used 
tail vein injection route of administration which best allows for investigation 
of tissue tropism and allows tissue-specific expression if tissue specific 
promoters/enhancers are used in conjunction with the desired serotype. 
Immunodeficient CB17SC mice were chosen in order to assess efficiency 
without the complication of antibody response to the transgene product (Y. 
Liu et al., 2004). A dose of 5x109vg was injected into each mouse and 
analysis done using a bioluminescence imaging system. AAV9 has been 
reported to stand out as an attractive vehicle for high transduction levels in 
cardiac and skeletal tissues (VandenDriessche et al. 2007; Bostick et al. 
2007; Pacak et al. 2008; Inagaki et al. 2006). Consistent with these reports, 
we also observed efficient transduction and robust luciferase levels of 
expression in the skeletal and cardiac tissue following intravenous 
administration. In a study Wang et al., 2008 also showed that neonatal mice 
respond more efficiently following intravenous administration of AAV 
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vector in heart and muscles gene transfer compared to adult mice that also 
showed expression but was less efficient. Our results concurred with these 
findings since we obtained significant levels of expression in cardiac and 
skeletal after intravenous administration of vector to newborn mice 48hrs 
old. Further exploration of age associated difference in AAV9 transduction 
may have significant clinical applications.  
When the skeletal muscles were examined by measuring 
photons/sec/cm2/sr there was expression of the transgene product but it was 
not as strong and impressive as in the heart muscles. The levels were much 
lower than expected despite the fact that the design of our expression cassette 
incorporated SPc5-12 promoter intended to maximize transgene expression 
to skeletal muscles (li et al., 1999). SPc5-12 promoter contains a 
combination of muscle specific transcriptional regulatory elements SREs, E-
boxes, MEF -2, MEF-1 and SP1 that has been reported to be responsible for 
long-term transgene expression and up regulation of expression 
predominantly in the cardiac and skeletal muscles both in neonatal and adult 
mice in vivo (Li et al., 1999). Pacak et al.,2008 and Aikawa et al.,2002 
demonstrated that efficient viral transduction of muscles require direct 
injections into a specified tissue or at least injection into the arterial supply 
of target muscle to help concentrate transduction to that exact location . 
Furthermore, Mary Mc Menamin also observed expression of micro-
dystrophin in AAV1 at high levels was via intramuscular and intraperitoneal 
administration but not via intravenous route of administration. Gregorevic et 
al., 2008 demonstrated that the use of AAV6 in conjunction with 10ug 
VEGF also allowed a widespread transduction of most skeletal and cardiac 
muscles. Moreover Intravenous technique using pressure has also 
demonstrated its easiness and efficiency to delivery in skeletal muscles in 
several species  though skeletal muscle in general, may prove difficult to 
transduce upon systemic administration of AAV due to blood vessel barriers 
(Z. Wang, T. Zhu, et al., 2005). However, most studies including our own 
have utilized the intravenous pathway for AAV9 delivery since it has the 
advantage of reaching most organs in the body when gene therapy vector is 
introduced into the bloodstream compared to localized transduction. The 
utilization of AAV9 with the use of a robust and muscle specific promoter 
allows for efficient systematic gene delivery specifically to the skeletal and 
heart muscles. Our finding is therefore important for the potential use of 
AAV9 for gene therapy of muscle related diseases such as Duchene 
Muscular Dystrophy and Myotonic dystrophy. Since superior cardiac 
transduction may have been recognized as a feature of AAV9 following 
intravenous injection with a dose of 5x109, dose response experiment using 
different doses is ongoing in the lab to examine the potency and kinetics of 
gene expression at lower and higher doses of viral particles. This is to assess 
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whether expression is dose depedent and determine if high efficiency can 
still be conferred in the heart and skeletal when the SPc5-12 muscle specific 
restrictive promoter is maintained at a higher or lower dose. Skeletal muscles 
are composed of fast twitch muscle fibers that depends mainly on glycolytic 
energy and slow twitch myofiber that depends on oxidation energy for 
metabolism in the muscles (Dunant et al., 2003: Giger et al.,2005). In our 
study we used SPc5-12 promoter construct to evaluate whether there was any 
selectivity for expression within fast twitch glycolytic muscles because 
DMD involves preferential loss and or degeneration of large glycolytic fast 
muscle fibers compared to the slow twitch oxidative muscle fibers (Dunant 
et al., 2003). The use of fast twitch muscle promoters can lead to sufficient 
transgene expression which might be of particular clinical relevance. It has 
also been shown that AAV2 preferentially transduces slow twitch fibers 
while AAV6 transduces both fiber types though it still wasn’t clear whether 
AAV9 displays a fiber type preference (Gosh et al., 2006). In our experiment 
detailed analysis of tissue biodistribution of the luciferase revealed that luc2 
expression driven by SPc5-12 promoter was predominant in the 
gastrocnemius, tibialis and quadriceps which are fast twitch muscles. The 
transgene was not expressed in other tissues like spleen, brain, kidney, liver, 
lung and diaphragm. This observation clearly showed that the combination 
of AAV9 and use of SPc5-12 promoter led to a significant gene transfer 
particularly in fast twitch muscles. This is an important observation and has 
important implication for gene therapy for DMD. 
  
Conclusion and Prospects  
This study confirmed that the SPc5-12 promoter delivered by AAV9 
serotype is robust and muscle specific. Experiments are in progress to 
determine if the SPc5-12 promoter is truly muscle specific when a 
provocative AAV9 vector dose is used. Other potentially novel muscle 
specific promoters such as MYOD1 and MYLK2 identified using the DDM 
algorithm are to be compared side by side with the SPc5-12 promoter in 
future experiments to identify the most robust and specific promoter. Since 
glycolytic muscle fibers are more vulnerable to the dystrophic process in 
DMD, comprehensive studies should further be conducted to examine in 
detail and compare the activity/ expression of muscle specific promoters in 
the main representative fast twitch (tibialis anterior, quadriceps, 
gastrocnemius) and slow twitch skeletal muscles tissues i.e. Soleus and 
Extensor Digitorum Longus (EDL). All these findings could later on be used 
to improve constructs of gene therapy for DMD and explored as 
experimental tools particularly to validate therapeutic approaches in animal 
disease models. 
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